Organization | NantCell, Inc.

NantCell, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Seattle WA United States (2003)

Status: Acquired by ImmunityBio, Inc. (2020)

Organization Overview

First Clinical Trial

2006

NCT00974896

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Etubics Corporation | NantCell, Inc.

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: NantCell, Inc. (1) Acquired (3)

alt-803 (10 trials)

bacille calmette-guerin (2 trials)

ganitumab (12 trials)

gemcitabine (gemzar) (5 trials)

Drugs in Phase 2 Trials (30)

Key: NantCell, Inc. (16) Acquired (14)

ad-cea vaccine (1 trial)

alpelisib (Piqray) (1 trial)

alt-801 (6 trials)

alt-836 (2 trials)

atezolizumab (Tecentriq) (1 trial)

autologous mononuclear stem cell (1 trial)

autologous natural killer cells (1 trial)

avelumab (bavencio) (2 trials)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (3 trials)

conatumumab (3 trials)

elotuzumab (empliciti) (1 trial)

etbx-011 (7 trials)

etbx-051 (6 trials)

etbx-061 (7 trials)

etoposide (vepesid) (1 trial)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (1 trial)

fulvestrant (faslodex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

melphalan (alkeran) (1 trial)

n803 (3 trials)

nivolumab (opdivo) (2 trials)

nk-92 (8 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (2 trials)

rilotumumab (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 1 Trials (9)

Key: NantCell, Inc. (2) Acquired (7)

allogeneic natural killer cells (1 trial)

ciml nk (1 trial)

cytarabine (cytosar-u) (1 trial)

everolimus (zortress) (1 trial)

fludarabine (fludara) (1 trial)

ipilimumab (yervoy) (1 trial)

panitumumab (vectibix) (1 trial)

sargramostim (leukine) (1 trial)

tnx-832 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Desmoplastic Small Round Cell Tumor (Phase 2)

Endocrine Gland Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Pancreatic Neoplasms (Phase 3)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 44
# of Trial APIs: 43